Paradise Jack L, Bluestone Charles D, Colborn D Kathleen, Bernard Beverly S, Rockette Howard E, Kurs-Lasky Marcia
Department of Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213-2583, USA.
Pediatrics. 2002 Jul;110(1 Pt 1):7-15. doi: 10.1542/peds.110.1.7.
In previous clinical trials involving children severely affected with recurrent throat infection (7 or more well-documented, clinically important, adequately treated episodes of throat infection in the preceding year, or 5 or more such episodes in each of the 2 preceding years, or 3 or more such episodes in each of the 3 preceding years), we found tonsillectomy efficacious in reducing the number and severity of subsequent episodes of throat infection for at least 2 years. The results seemed to warrant the election of tonsillectomy in children meeting the trials' stringent eligibility criteria but also provided support for nonsurgical management. We undertook the present trials to determine 1) whether tonsillectomy would afford equivalent benefit in children who were less severely affected than those in our earlier trials but who nonetheless had indications for tonsillectomy comparable to those in general use, and 2) whether, in such children, the addition of adenoidectomy would confer additional benefit.
We conducted 2 parallel randomized, controlled trials in the Ambulatory Care Center of Children's Hospital of Pittsburgh. To be eligible, children were required to have had a history of recurrent episodes of throat infection that met standards slightly less stringent than the standards used in our earlier trials regarding either the frequency of previous episodes or their clinical features or their degree of documentation, but not regarding >1 of those parameters. These reduced standards were nonetheless more stringent than those in current official guidelines, which list "3 or more infections of tonsils and/or adenoids per year despite adequate medical therapy" as an indication for tonsillectomy or adenotonsillectomy. Of 2174 children referred by physicians or parents, 373 met the current trials' eligibility criteria and 328 were enrolled. Of these, 177 children without obstructing adenoids or recurrent or persistent otitis media were randomized to either a tonsillectomy group, an adenotonsillectomy group, or a control group (the 3-way trial), and 151 children who had 1 or more such conditions were randomized to either an adenotonsillectomy group or a control group (the 2-way trial). Outcome measures were the occurrence of episodes of throat infection during the 3 years of follow-up; other, indirect measures of morbidity; and complications of surgery.
By various measures, the incidence of throat infection was significantly lower in surgical groups than in corresponding control groups during each of the 3 follow-up years. However, even among control children, mean rates of moderate or severe episodes were low, ranging from 0.16 to 0.43 per year. Adenotonsillectomy was no more efficacious than tonsillectomy alone. Of 203 children treated with surgery, 16 (7.9%) had surgery-related complications of varying types and severity.
The modest benefit conferred by tonsillectomy or adenotonsillectomy in children moderately affected with recurrent throat infection seems not to justify the inherent risks, morbidity, and cost of the operations. We conclude that, under ordinary circumstances, neither eligibility criteria such as those used for the present trials nor the criterion for surgery in current official guidelines are sufficiently stringent for use in clinical practice.
在之前涉及严重复发性咽喉感染儿童的临床试验中(前一年有7次或更多记录良好、具有临床重要性且得到充分治疗的咽喉感染发作,或前两年每年有5次或更多此类发作,或前三年每年有3次或更多此类发作),我们发现扁桃体切除术在至少两年内可有效减少后续咽喉感染发作的次数和严重程度。这些结果似乎表明,对于符合试验严格入选标准的儿童,选择扁桃体切除术是合理的,但同时也为非手术治疗提供了支持。我们进行了本试验,以确定:1)对于病情不如早期试验中严重但仍有与一般使用情况相当的扁桃体切除指征的儿童,扁桃体切除术是否能带来同等益处;2)在这类儿童中,加做腺样体切除术是否会带来额外益处。
我们在匹兹堡儿童医院门诊护理中心进行了两项平行的随机对照试验。符合条件的儿童需有复发性咽喉感染病史,其发作频率、临床特征或记录程度的标准比我们早期试验所用标准略宽松,但不能超过其中一项参数。然而,这些降低后的标准仍比当前官方指南更为严格,官方指南将“尽管进行了充分的药物治疗,但每年仍有3次或更多扁桃体和/或腺样体感染”列为扁桃体切除术或腺样体扁桃体切除术的指征。在医生或家长转诊的2174名儿童中,373名符合当前试验的入选标准,328名被纳入研究。其中,177名没有腺样体阻塞或复发性或持续性中耳炎的儿童被随机分为扁桃体切除组、腺样体扁桃体切除组或对照组(三向试验),151名有1项或更多此类病症的儿童被随机分为腺样体扁桃体切除组或对照组(双向试验)。观察指标为随访3年内咽喉感染发作的情况;其他间接的发病指标;以及手术并发症。
通过各种测量方法,在3年随访期的每一年中,手术组咽喉感染的发生率均显著低于相应的对照组。然而,即使在对照组儿童中,中度或重度发作的平均发生率也很低,每年为0.16至0.43次。腺样体扁桃体切除术并不比单纯扁桃体切除术更有效。在203名接受手术治疗的儿童中,16名(7.9%)出现了不同类型和严重程度的手术相关并发症。
扁桃体切除术或腺样体扁桃体切除术对中度复发性咽喉感染儿童带来的益处不大,似乎无法证明手术固有的风险、发病率和成本是合理的。我们得出结论,在一般情况下,无论是本试验所用的入选标准还是当前官方指南中的手术标准,都不够严格,不足以用于临床实践。